Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

994
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
994
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

468
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
468
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

820
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

726
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
726
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis-Associated Lung Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Prognostic significance of 1-year pulmonary function changes in inflammatory myopathy-related interstitial lung disease.

Seminars in arthritis and rheumatism·2026
Same author

Fitbit as an activity monitor in idiopathic inflammatory myopathy: results from a real-world cohort.

Clinical and experimental rheumatology·2026
Same author

Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis.

Clinical and experimental rheumatology·2026
Same author

Multimodal Integration of Protein Interactomes With Genomic and Molecular Data Discovers Distinct Rheumatoid Arthritis Endotypes.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Detection of dermatomyositis skin rashes in skin of color: Addressing critical training gaps.

The American journal of medicine·2026

Related Experiment Video

Updated: Apr 17, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subgroups: Insights From a Single-Center Cohort.

Nantakarn Pongtarakulpanit1, Sidra Tahir2, Varshapriya Suresh2

  • 1N. Pongtarakulpanit, MD, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA, and Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

The Journal of Rheumatology
|April 15, 2026
PubMed
Summary

Remission rates in idiopathic inflammatory myopathy (IIM) vary by subtype, with dermatomyositis (DM) showing the highest rates. Anti-Mi-2 antibodies predict a better chance of remission, improving patient survival.

Keywords:
cohort studiesdermatomyositismyositisprognosisremission induction

More Related Videos

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

6.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

6.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Idiopathic inflammatory myopathies (IIM) are a group of rare autoimmune diseases characterized by chronic muscle inflammation.
  • Understanding remission rates and predictors is crucial for optimizing treatment strategies and improving patient outcomes in IIM.
  • Previous studies have reported varying remission rates, but subgroup-specific data and predictor analyses are less common.

Purpose of the Study:

  • To evaluate and compare remission rates across different idiopathic inflammatory myopathy (IIM) subgroups.
  • To identify predictors of remission in adult IIM patients.
  • To assess the association between remission and mortality in IIM.

Main Methods:

  • Analysis of a prospective registry of adult IIM patients with at least one year of disease duration (2000-2019).
  • Subgroup classification into dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM).
  • Evaluation of remission, drug-free remission (DFR), and International Myositis Assessment and Clinical Studies Group (IMACS) remission using survival analysis and Cox proportional hazards models.

Main Results:

  • The cohort comprised 393 patients (67.2% female, mean age 50.1 years).
  • At 10 years, cumulative probabilities for remission, DFR, and IMACS remission were 40.3%, 23.3%, and 18.1%, respectively.
  • Remission rates were highest in DM (47.4%) and lowest in ASyS (30.1%). Anti-Mi-2 antibody positivity was associated with a higher likelihood of remission (HR 2.08, p=0.020). Remission and DFR correlated with improved survival.

Conclusions:

  • Remission rates in IIM significantly differ among subgroups, with DM demonstrating the most favorable outcomes and ASyS the least.
  • The presence of anti-Mi-2 antibodies is a positive predictor for achieving remission in IIM patients.
  • Achieving remission and drug-free remission is linked to improved survival in individuals with idiopathic inflammatory myopathies.